ClinicalTrials.gov
ClinicalTrials.gov Menu

VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01253551
Recruitment Status : Completed
First Posted : December 3, 2010
Last Update Posted : October 16, 2012
Sponsor:
Collaborator:
Vertex Pharmaceuticals Incorporated
Information provided by (Responsible Party):
Tibotec BVBA

December 2, 2010
December 3, 2010
October 16, 2012
December 2010
Not Provided
  • Blood levels of telaprevir and raltegravir when given alone versus when given together [ Time Frame: Day 7 of Treatment A ]
  • Blood levels of telaprevir and raltegravir when given alone versus when given together [ Time Frame: Day 4 of Treatment B ]
  • Blood levels of telaprevir and raltegravir when given alone versus when given together [ Time Frame: Day 11 of Treatment B ]
Same as current
Complete list of historical versions of study NCT01253551 on ClinicalTrials.gov Archive Site
  • Percentage of participants with a given adverse event as a measure of safety and tolerability [ Time Frame: From screening to end of study ]
  • Clinical laboratory abnormalities as a measure of safety and tolerability [ Time Frame: At screening and at 5-7 days and 30-32 days after last dose (Treatment A or B) ]
  • Clinical laboratory abnormalities as a measure of safety and tolerability [ Time Frame: On Days 1 and 7 (Treatment A) ]
  • Clinical laboratory abnormalities as a measure of safety and tolerability [ Time Frame: On Days 1, 4, and 11 (Treatment B) ]
  • Vital signs observed values and changes from baseline as a measure of safety and tolerability [ Time Frame: At screening and at 5-7 days and 30-32 days after last dose (Treatment A or B) ]
  • Vital signs observed values and changes from baseline as a measure of safety and tolerability [ Time Frame: On Days 1 and 7 (Treatment A) ]
  • Vital signs observed values and changes from baseline as a measure of safety and tolerability [ Time Frame: On Days 1, 4, and 11 (Treatment B) ]
  • Physical examination findings and changes from baseline as a measure of safety and tolerability [ Time Frame: At screening, on Day -1 of Treatments A and B, and at 5-7 days and 30-32 days after last dose (Treatment A or B) ]
  • Vital signs observed values and changes from baseline as a measure of safety and tolerability [ Time Frame: At screening and at 5-7 days and 30-32 days after last dose (Treatment A or B) ]
  • Vital signs observed values and changes from baseline as a measure of safety and tolerability [ Time Frame: On Days 1 and 7 (Treatment A) ]
  • Vital signs observed values and changes from baseline as a measure of safety and tolerability [ Time Frame: On Days 1, 4, and 11 (Treatment B) ]
  • Physical examination findings and changes from baseline as a measure of safety and tolerability [ Time Frame: At screening, on Day -1 of Treatments A and B, and at 5-7 days and 30-32 days after last dose (Treatment A or B) ]
  • Percentage of participants with a given adverse event as a measure of safety and tolerability [ Time Frame: From screening to end of study ]
  • Clinical laboratory abnormalities as a measure of safety and tolerability [ Time Frame: At screening and at 5-7 days and 30-32 days after last dose (Treatment A or B) ]
  • Clinical laboratory abnormalities as a measure of safety and tolerability [ Time Frame: On Days 1 and 7 (Treatment A) ]
  • Clinical laboratory abnormalities as a measure of safety and tolerability [ Time Frame: On Days 1, 4, and 11 (Treatment B) ]
Not Provided
Not Provided
 
VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir
A Phase 1, Open-label, Randomized, Crossover Study in 20 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Raltegravir, Both at Steady-state
The purpose of this study is to confirm the absence of a clinically relevant interaction between telaprevir and raltegravir at steady-state.Telaprevir is being investigated for the treatment of chronic hepatitis C virus infection, and raltegravir is used to treat HIV infection.
This is an open-label, randomized (the order in which you receive the treatment sessions is determined by chance, like tossing a coin), crossover (participants will receive different interventions sequentially during the trial) study in healthy participants to investigate the effect of telaprevir 750 mg, every 8 hours, on the pharmacokinetics (how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body) of raltegravir 400 mg, twice a day, and vice versa. The study population will consist of 20 healthy participants. Each individual participant will receive two treatments: Treatment A (telaprevir 750 mg, every 8 hours, alone, on Days 1 to 6, with a morning dose on Day 7) and Treatment B (raltegravir 400 mg, twice a day, on Days 1 to 10 and telaprevir 750 mg, every 8 hours, on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11). Half of the participants will receive first Treatment A and then Treatment B; the other half will receive first Treatment B and then Treatment A. There will be a washout period of at least 14 days between the 2 sessions. The screening period will be maximum 21 days; the treatment duration will be approximately 4.5 weeks, and the follow-up period will be 30 to 31 days. All study medication will be taken with food. On Day 7 of Treatment A and Day 11 of Treatment B, 9 blood samples will be taken for determination of the levels of telaprevir in the blood. On Days 4 and 11 of Treatment B, 10 blood samples will be taken for determination of the levels of raltegravir in the blood. Predose pharmacokinetic samples will be collected on other days during the treatment sessions. Safety and tolerability will be evaluated throughout the trial by evaluating results of blood and urine analyses, vital signs, physical examinations, electrocardiograms (electrical recording of the heart), drug and alcohol screenings, and by assessing how the participant is feeling. In Treatment A, participants will receive 2 oral tablets of telaprevir 375 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. In Treatment B, participants will receive 1 oral tablet of 400 mg raltegravir twice a day on Days 1 to 10 and 2 oral tablets of 375 mg telaprevir every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hepatitis C
  • Drug: Treatment sequence AB
    Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
  • Drug: Treatment sequence BA
    Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
  • Experimental: 001
    Treatment sequence AB Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
    Intervention: Drug: Treatment sequence AB
  • Experimental: 002
    Treatment sequence BA Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
    Intervention: Drug: Treatment sequence BA
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
21
20
April 2011
Not Provided

Inclusion Criteria:

  • Healthy on the basis of physical examination, medical history, vital signs, electrocardiogram and clinical laboratory tests at screening
  • A Body Mass Index of 18.0 to 30.0 kg/m2, extremes included
  • Women must be postmenopausal for at least 2 years, be surgically sterile and should not be breastfeeding
  • Men must agree to use 2 highly effective methods of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of the study drug
  • Be non-smoking for at least 3 months prior to selection.

Exclusion Criteria:

  • Current use of prescription medication, regular treatment with over-the-counter medications (to be stopped no less than 7 days prior to first intake of study medication) or consumption of herbal medications or dietary supplements, vitamins, grapefruit or grapefruit juice, apple juice or orange juice within 14 days before first intake of study medication
  • Consumption of more than 2 units of alcoholic beverages per day or more than 14 units per week (1 unit of alcohol equals 1 glass of beer, 1 glass of wine, 25 mL shot of 40% spirit), consumption of alcohol 72 hours before or after study medication intake, consumption of an average of more than five 240 mL servings of coffee or other caffeinated beverages, eg, tea, cola per day
  • History or evidence of current use of alcohol, barbiturate, amphetamine, recreational or narcotic drug use
  • Received an investigational drug or vaccine or used an investigational medical device within 3 months or 5 half lives (whichever is longer) before the planned start of treatment or having participated previously in a study with telaprevir.
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT01253551
CR017608
VX-950HEP1001
Not Provided
Not Provided
Not Provided
Tibotec BVBA
Tibotec BVBA
Vertex Pharmaceuticals Incorporated
Study Director: Tibotec-Virco Virology BVBA Clinical Trial Tibotec BVBA
Tibotec BVBA
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP